<DOC>
	<DOCNO>NCT01146548</DOCNO>
	<brief_summary>This French national trial , conduct use double-blind , placebo-controlled , randomised design involve 15 center 88 patient sex . The primary objective trial evaluate effect selective inhibitor serotonin reuptake , Fluoxétine , high dose ( 40 mg/day ) usually recommend depressed patient , three month patient suffer atypical Parkinson 's disease call Multiple System Atrophy , compare placebo effect . Secondary objective trial evaluation effect Fluoxétine six week dose 20 mg/day , six month dose 40mg/day , assess effect mortality , quality life , autonomic disorder , particularly orthostatic hypotension , mood others symptoms sleep , apathy , pain fatigue .</brief_summary>
	<brief_title>Fluoxetine Multiple System Atrophy Patients</brief_title>
	<detailed_description>Fluoxetine first introduce dose 20 mg/day six week dose increase 40 mg/day . If patient side effect dose 40 mg/day , dose may reduce 20 mg/day . Assessment visit conduct 6 week , 3 month , 6 month treatment . After 6 month , trial 's treatment fluoxetine discontinue gradually . A new assessment conduct one month end treatment . The expected result demonstration improve score scale UMSARS 3 6 month fluoxetine group compare placebo group .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Female Male Patient Multiple System Atrophy 's disease diagnose accord international consensus criterion ( Gilman 's criterion ) Patient 30 80 year age Patient present cognitive problem could impair comprehension patient participation protocol Patient receive antiparkinsonian treatment ( applicable ) stable dose least 2 month enter study , expectation treatment remain unchanged throughout course patient participation trial Patient receive symptomatic treatment autonomic disorder ( applicable ) stable dose least 2 month enter study , expectation treatment remain unchanged throughout course patient participation trial Signed informed consent obtain Patient eligible social security ( specific requirement French law ) Patient present major swallow problem take capsule Patient already receive selective inhibitor serotonin reuptake antidepressant , patient receive one 3 month precede start study Patient major depressive syndrome investigator considers indication antidepressant seem essential Bedridden patient confine wheelchair whole day Patient severe hyponatremia Patient another Parkinsonian 's syndrome Multiple System Atrophy ( type atypical Parkinson 's disease , progressive supra nuclear paralysis , corticobasal degeneration ) Patient dementia Patient MiniMental State Exam score &lt; 24 Patient unable understand protocol another endpoint consider clinical trial 's process Patient chronic disease affect development assessment patient trial Patient receiving concomitant medication could affect evaluation outcome measure ( e.g . neuroleptic assessment parkinsonian symptom , vasodilator assessment orthostatic hypotension , sedative drug prescribe day assessment daytime sleepiness , apathy fatigue ) Patient absolute relative contraindication Fluoxetine ( hypersensitivity Fluoxetine , patient history epilepsy , manic state , severe hepatic renal impairment , skin bleeding , severe heart , uncontrolled diabete , patient treat selective non selective IMAO ) Person : ward state prisoner ( requirement french law ) Patient pregnant risk , nurse mother</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Fluoxetine effect</keyword>
	<keyword>Multiple System Atrophy</keyword>
	<keyword>MSA</keyword>
</DOC>